Melittin, a Honey Bee Venom Peptide, Exhibits Broad Anti-Cancer Properties Across Diverse Preclinical Models

The field of AllergoOncology explores how allergen-derived molecules can be repurposed as anti-cancer agents, offering novel therapeutic avenues. Traditional cancer treatments often face challenges with specificity and systemic toxicity, leading to significant side effects and limited efficacy in advanced stages. Melittin, a peptide comprising 40%-50% of honey bee venom, has emerged as a potent candidate due to its diverse anti-tumor mechanisms. Despite its well-known role as a mast cell activator and allergen, its ability to target cancer cells through multiple pathways positions it as a promising, yet challenging, therapeutic agent.

This EAACI Task Force Position Paper synthesizes current preclinical evidence on melittin's anti-cancer properties, integrating findings from numerous studies. Researchers evaluated diverse cancer models to characterize melittin's mechanisms of action, including direct cell death induction, inhibition of key oncogenic pathways, and modulation of the tumor microenvironment. The paper also critically assessed the barriers to clinical translation, specifically addressing melittin's intrinsic haemolytic activity, systemic toxicity, and high allergenic potential, while exploring advanced nanotechnology and targeted delivery strategies.

Preclinical evidence consistently demonstrates that melittin induces cancer cell death through multiple distinct mechanisms. It causes direct membrane disruption, triggers mitochondrial and death receptor-mediated apoptosis, and initiates ferroptosis. Furthermore, melittin effectively inhibits crucial oncogenic pathways, including PI3K/Akt/mTOR, NF-κB, and HIF-1α/VEGF signaling.

Additional significant effects include the suppression of angiogenesis, inhibition of epithelial-mesenchymal transition (EMT), reduction of invasion, and prevention of metastatic dissemination across various cancer models. Melittin also modulates the tumor immune microenvironment, suggesting a multifaceted approach to cancer therapy. However, its clinical translation is significantly limited by its inherent haemolytic activity, systemic toxicity, and potent allergenic properties, which necessitate innovative delivery solutions.